bevacizumab + cyclophosphamide + docetaxel + epirubicin + trastuzumab

This is a multi-agent combination regimen consisting of five drugs: - **Bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A, VEGF-A, inhibiting angiogenesis) - **Cyclophosphamide** (an alkylating agent that crosslinks DNA, leading to cell death) - **Docetaxel** (a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division) - **Epirubicin** (an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II) - **Trastuzumab** (a monoclonal antibody targeting the human epidermal growth factor receptor 2, HER2) This regimen has been studied as neoadjuvant or adjuvant therapy for HER2-positive locally advanced or inflammatory breast cancer. The combination aims to maximize antitumor efficacy by combining cytotoxic chemotherapy with targeted therapies against angiogenesis and HER2 signaling. Cardiac safety is a key consideration due to the potential for cardiotoxicity from both anthracyclines and anti-HER2/VEGF agents[1][3][4].